Evidence map›Paper›PMID 34940684›Full record

ArticleMarine drugs2021

Anti-SARS-CoV-2 Activity of Rhamnan Sulfate from

Yuefan Song, Peng He, Andre L Rodrigues, Payel Datta, Ritesh Tandon, John T Bates, Michael A Bierdeman, Chen Chen, Jonathan Dordick, Fuming Zhang and 1 more

Open access · goldAbstract read
In one paragraph

Article in Marine drugs, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 48 citations in OpenAlex.

  1. In Vitro Antiviral Activity of Red Algae Extracts fromTropical medicine and infectious disease · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Yuefan SongDepartments of Chemistry and Chemical Biology, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY 12180, USA.ORCID 0000-0002-0151-2046
Peng HeDepartments of Chemistry and Chemical Biology, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY 12180, USA.
Andre L RodriguesDepartment of Chemical and Biological Engineering, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY 12180, USA.ORCID 0000-0001-8364-3025
Payel DattaDepartments of Chemistry and Chemical Biology, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY 12180, USA.
Ritesh TandonDepartment of Microbiology and Immunology, University of Mississippi Medical Center, Jackson, MS 39216, USA.ORCID 0000-0001-8996-8840
John T BatesDepartment of Microbiology and Immunology, University of Mississippi Medical Center, Jackson, MS 39216, USA.ORCID 0000-0001-5545-6871
Michael A BierdemanDepartment of Medicine, University of Mississippi Medical Center, Jackson, MS 39216, USA.
Chen ChenCalroy Health Sciences, LLC., Scottsdale, AZ 85260, USA.
Jonathan DordickDepartment of Chemical and Biological Engineering, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY 12180, USA.
Fuming ZhangDepartment of Chemical and Biological Engineering, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY 12180, USA.ORCID 0000-0003-2803-3704
Robert J LinhardtDepartments of Chemistry and Chemical Biology, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY 12180, USA.ORCID 0000-0003-2219-5833
Rensselaer Polytechnic Institute · USUniversity of Mississippi Medical Center · US

Funding

National Science Foundation DMR-1933525
6 · The paper itself

Abstract

The COVID-19 pandemic is a major human health concern. The pathogen responsible for COVID-19, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), invades its host through the interaction of its spike (S) protein with a host cell receptor, angiotensin-converting enzyme 2 (ACE2). In addition to ACE2, heparan sulfate (HS) on the surface of host cells also plays a significant role as a co-receptor. Our previous studies demonstrated that sulfated glycans, such as heparin and fucoidans, show anti-COVID-19 activities. In the current study, rhamnan sulfate (RS), a polysaccharide with a rhamnose backbone from a green seaweed,

Indexed as

COVID-19 Drug TreatmentSeaweedAntiviral AgentsAquatic OrganismsDeoxy SugarsHumansMannansPlant ExtractsProtein BindingSARS-CoV-2Spike Glycoprotein, CoronavirusStructure-Activity RelationshipAntiviral AgentsDeoxy SugarsMannansPlant ExtractsrhamnanSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2heparinrhamnan sulfateSARS-CoV-2surface plasmon resonance

Identifiers

PMID34940684
PMCPMC8707894
OpenAlexW3215879816

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.